An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia Marjanne A. PienaNatalie HouwingCraig Bennison Original Research Article Open access 08 October 2021 Pages: 121 - 131
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective Adnan AlsumaliLaurence M DjatcheDominik Lautsch Original Research Article Open access 08 October 2021 Pages: 1343 - 1354
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review Thitima KongnakornGrammati SarriXinke Zhang Systematic Review Open access 01 October 2021 Pages: 183 - 201
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates Laura C. EdneyJames LomasJessica Ochalek Review Article 29 September 2021 Pages: 31 - 43
Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations Daniel GallacherPeter KimaniNigel Stallard Original Research Article Open access 28 September 2021 Pages: 109 - 120
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic Yumi AsukaiAndrew BriggsDaniel A. Ollendorf Current Opinion Open access 24 September 2021 Pages: 1201 - 1208
Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies T. Joseph Mattingly IIR. Brett McQueenPei-Jung Lin Current Opinion 23 September 2021 Pages: 1101 - 1107
Authors’ Response to “Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery” Bert AvauHans Van RemoortelPhilippe Vandekerckhove Letter to the Editor 15 September 2021 Pages: 137 - 138
Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery Kevin M. TrentinoHamish MaceAxel Hofmann Letter to the Editor 15 September 2021 Pages: 133 - 135
Comment on “Deterministic Sensitivity Analysis Under Ignorance” Rick A. VremanJoost W GeenenWim G. Goettsch Letter to the Editor 15 September 2021 Pages: 1199 - 1199
Deterministic Sensitivity Analysis Under Ignorance Afschin Gandjour Letter to the Editor Open access 15 September 2021 Pages: 1197 - 1198
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis Laurenske A. VisserMarc FolcherWilliam Ken Redekop Original Research Article Open access 04 September 2021 Pages: 91 - 108
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe Natalie BohmSarah BerminghamHamish Laing Review Article Open access 04 September 2021 Pages: 13 - 29
Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic Samare P. I. HulsAyesha SajjadJob van Exel Original Research Article Open access 02 September 2021 Pages: 77 - 90
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom Maria Veronica DorgaliAlberto LongoMarco Boeri Original Research Article 30 August 2021 Pages: 65 - 76
Why the Gap in Evaluating the Social Constructs and the Value of Medicines? Jacquelyn McRaeEberechukwu Onukwugha Current Opinion 30 August 2021 Pages: 1365 - 1372
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Sabine E. GrimmBen WijnenManuela A. Joore Review Article Open access 27 August 2021 Pages: 1397 - 1410
Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis Lidia EngelStirling BryanDavid G. T. Whitehurst Review Article 23 August 2021 Pages: 1383 - 1395
A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper Mikyung Kelly SeoMark Strong Practical Application Open access 20 August 2021 Pages: 1373 - 1381
What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK Liz MorrellJames BuchananSarah Wordsworth Original Research Article Open access 19 August 2021 Pages: 1443 - 1454
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer Martijn J. H. G. SimonsValesca P. RetèlManuela A. Joore Original Research Article Open access 18 August 2021 Pages: 1429 - 1442
Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment Bassem AskerRaghad JawadHaidar Jarallah Original Research Article Open access 16 August 2021 Pages: 1327 - 1341
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome I-Wen PanDaniel M. HalperinYa-Chen Tina Shih Systematic Review 11 August 2021 Pages: 1271 - 1297
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial Michael DolphGabriel TremblayHoyee Leong Original Research Article Open access 09 August 2021 Pages: 1309 - 1325
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment Michael SchlanderKarla Hernandez-VillafuerteMichael Baumann Systematic Review Open access 09 August 2021 Pages: 1243 - 1269
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature Boshen JiaoAnirban BasuBeth Devine Review Article 09 August 2021 Pages: 1225 - 1241
The Challenges of Measuring Informal Care Time: A Review of the Literature Sean UrwinYiu-Shing LauMatt Sutton Review Article Open access 29 July 2021 Pages: 1209 - 1223
A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement Jihyung HongEun-Young Bae Review Article 28 July 2021 Pages: 1109 - 1121
EQ-5D-Y Population Norms for Japanese Children and Adolescents Takeru ShiroiwaTakashi Fukuda Original Research Article Open access 22 July 2021 Pages: 1299 - 1308
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments Sabine E. GrimmXavier PouwelsManuela A. Joore Original Research Article Open access 19 July 2021 Pages: 1185 - 1196
Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening Edna KeeneyHoward ThomSabina Sanghera Letter to the Editor 17 July 2021 Pages: 969 - 970
Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening” James F. O’Mahony Letter to the Editor 17 July 2021 Pages: 965 - 967
Lifetime Costs for Treated Follicular Lymphoma Patients in the US Caitlin EichtenQiufei MaRichard T. Maziarz Original Research Article 17 July 2021 Pages: 1163 - 1183
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review Simon van der PolPaula Rojas GarciaAntoinette D. I. van Asselt Systematic Review Open access 15 July 2021 Pages: 1411 - 1427
Valuing SF-6Dv2 in Australia Using an International Protocol Brendan MulhernRichard NormanJohn Brazier Original Research Article 12 July 2021 Pages: 1151 - 1162
Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis Bert AvauHans Van RemoortelPhilippe Vandekerckhove Systematic Review Open access 08 July 2021 Pages: 1123 - 1139
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel Karen M. FaceyJaime EspinSheela Upadhyaya Original Research Article Open access 07 July 2021 Pages: 1021 - 1044
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease: A Swedish Register-Based Study in 1823 Observations Jenny M. NorlinKlas KellerborgPer Odin Original Research Article 07 July 2021 Pages: 1141 - 1149
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment Aureliano Paolo FinchEva Gamperthe EORTC Quality of Life Group Original Research Article Open access 03 July 2021 Pages: 1085 - 1098
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries Kate WilliamsDaniel AggioYan Wang Original Research Article Open access 01 July 2021 Pages: 901 - 912
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework Luca M. M. JanssenRuben M. W. A. DrostSilvia M. A. A. Evers Scoping Review Open access 25 June 2021 Pages: 983 - 993
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review Joseph Khoa HoKennedy BorleLarry D. Lynd Systematic Review 22 June 2021 Pages: 995 - 1019
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT) Michael J. ZorattiKelvin K. W. Chanthe Health Utility Book (HUB) Working Group Original Research Article 21 June 2021 Pages: 1075 - 1084
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study Becky PenningtonAbualbishr AlshreefJohn Brazier Correction Open access 19 June 2021 Pages: 1099 - 1099
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies Ana DuarteSimon WalkerMark Sculpher Review Article 19 June 2021 Pages: 879 - 887
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine Erin KirwinEllen RaffertyChristopher McCabe Original Research Article Open access 17 June 2021 Pages: 1059 - 1073
Retraction Note to: The EQ-5D-5L Valuation Study in Egypt Sahar A. Al ShabasyMaggie M. AbbassiSamar F. Farid Retraction Note Open access 15 June 2021 Pages: 971 - 971
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector Irina PokhilenkoLuca M. M. JanssenAggie T. G. Paulus Systematic Review Open access 14 June 2021 Pages: 889 - 900
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia Anna Reyes-TravéLaura Guarga-SoléJoaquín Delgadillo-Duarte Practical Application Open access 10 June 2021 Pages: 973 - 982
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective Daniel StellatoMarroon E. ThabaneThomas E. Delea Original Research Article 09 June 2021 Pages: 1045 - 1058
